HOME >> BIOLOGY >> NEWS
JCI Table of Contents

Analysis of the host response to anthrax lethal toxin suggests some current treatment strategies are inappropriate

Anthrax, a disease previously primarily relevant to the livestock-management community recently became a wordwide bioterrorism concern. However, human anthrax infection is primarily a result of direct or indirect contact with infected animals or exposure to contaminated animal products.

Bacillus anthracis, the causative agent of anthrax, is believed to induce disease and death in humans in an endotoxic shocklike manner.

A comprehensive study of the effects of anthrax lethal toxin in mice by Stephen Leppla and colleagues at the National Institutes of Health demonstrated that toxin-induced death does not result from septic shock mediated by cytokine release as previously thought, but via hypoxia-induced liver failure.

The study strongly suggests that the therapies developed for the treatment of cytokine-mediated septic shock will not be appropriate for the treatment of anthrax.

In an accompanying commentary, Alice Prince from Columbia University College of Physicians and Surgeons in New York states that "this analysis of the pathological effects of the B. anthracis lethal toxin should help focus future studies of optimal therapy for patients exposed to this organism.

These results make clear that anthrax patients exhibit a unique pathophysiology and should not be considered to have generic shock analogous to Gram-negative sepsis". Prince continues "exactly how the lethal factor produces such profound tissue hypoxia, what metabolic processes are affected in the liver and elsewhere, and how these effects may be blocked will require further studies".

TITLE: Bacillus anthracis lethal toxin induces TNF-alphaindependent hypoxia-mediated toxicity in mice

AUTHOR CONTACT:
Stephen Leppla
National Institutes of Health, Bethesda, Maryland, USA
Phone: 301-594-2865
Fax: 301-480-
'"/>

Contact: Brooke Grindlinger
science_editor@the-jci.org
212-342-9006
Journal of Clinical Investigation
2-Sep-2003


Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related biology news :

1. JCI Table of Contents, 15 July 2004
2. JCI Table of Contents, January 15 2004
3. JCI Table of Contents, November 3, 2003
4. JCI Table of Contents, 1 October, 2003
5. JCI Table of Contents, September 15, 2003
6. JCI Table of Contents, 15 August 2003
7. JCI Table of Contents, May 1, 2003
8. JCI Table of Contents, April 1, 2003
9. JCI Table of Contents, March 14, 2003
10. JCI Table of Contents, January 2, 2003
11. JCI Table of Contents, December 2, 2002

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/14/2018)... ... August 13, 2018 , ... NRD, LLC – NRD® is ... Ionizing Gun. , The ionizing gun features ergonomic design and rugged construction. ... filter and electropolished OSHA-compliant tip. This can be cleanroom packaged (P-2021-5502) or normally ...
(Date:8/14/2018)... ... August 14, 2018 , ... From ... movie “Wonder,” to a better understanding of congenital heart defects, 3-D printing is ... the latest special issue of Birth Defects Research (DOI: 10.1002/bdr2.1367). ...
(Date:8/7/2018)... ... 06, 2018 , ... Nurse practitioners and ... their healthcare careers in the past year, according to the second annual survey ... jobseekers with a wide variety of career- and employment-related resources including physician/candidate database, ...
Breaking Biology News(10 mins):
(Date:7/24/2018)... ... ... R3 Stem Cell is now offering regenerative therapies for COPD lung disease ... Certified providers, with outcomes significantly improving patient quality of life. , Traditional therapies for ... help repair and regenerate damaged lung tissues. Stem cell therapy for COPD ...
(Date:7/24/2018)... ... 24, 2018 , ... On August 6, 2018, BioMedGPS will ... Not just a pretty face, SmartTRAK 3.0’s latest improvements were inspired by its ... world’s first online and real-time data portal that specializes in providing competitive market ...
(Date:7/22/2018)... ... July 19, 2018 , ... Mitotech ... with Essex Bio-Investment for Phase 3 clinical program in Dry Eye Disease. Under ... SkQ1 with approximately $17m allocated towards the first Phase 3 study starting as ...
(Date:7/22/2018)... ... July 20, 2018 , ... ... automation and IT solutions with 150 employees on both the east and west ... Program. Superior Controls met the high criteria for application expertise, operational excellence ...
Breaking Biology Technology:
Cached News: